- Twist Bioscience Corporation TWST reported a 65% Y/Y increase in its third-quarter revenues to $35 million, beating the Wall Street estimate of $32.27 million, driven by strength in next-generation sequencing revenues.
- In the Q3 conference call, Twist said that next-generation sequencing (NGS) revenues were $18.7 million, up twofold from $9.1 million a year ago, driven by an expanding pipeline and an increase in the number of applications, including liquid biopsy.
- Synthetic biology revenues were $14.3 million, up 21% Y/Y. Biopharma revenue was approximately $2 million.
- Twist CFO Jim Thorburn said that healthcare is now Twist's largest market segment, representing nearly 50% of revenues, with $17.4 million, up more than twofold from $8.5 million a year ago.
- Industrial chemicals revenues were $8.4 million. The academic market provided revenues of $7.7 million.
- The firm's net loss widened to $(0.82) from $(0.67) a year ago. Analysts, on average, had estimated a net loss of $(0.75).
- It ended Q2 with $475.3 million in cash and cash equivalents and $44.1 million in short-term investments.
- FY21 Guidance: Twist raised revenue outlook to $129 million - $132 million (consensus $127.12 million), from $121 million - $129 million previously. This includes synthetic biology revenue of $54 million - $56 million, NGS revenue of $69 million - $70 million.
- It expects a net loss of approximately $(150) million, reflecting "increased investments in our commercial organization," the firm said in a statement.
- Price Action: TWST shares are down 10.60% at $110.99 during the market session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
